Nilotinib Eg (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, inhibiting its activity. This blocks downstream signaling pathways that drive leukemic cell growth and survival, leading to reduced proliferation and increased apoptosis of malignant cells.

The dose of Nilotinib Eg is determined by the prescribing clinician based on the patient’s disease status, prior therapy, and individual tolerance. Dosage regimens are individualized and should follow the prescribing information provided by the healthcare professional.

Safety of nilotinib in pregnancy and lactation has not been established. The drug is classified as having an unknown pregnancy category, and it is generally recommended to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk.

To order Nilotinib Eg, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor that offers higher potency and activity against many imatinib‑resistant BCR‑ABL mutations. Compared with imatinib, nilotinib often achieves faster and deeper molecular responses, but it may have a different safety profile, including a higher risk of QT prolongation.

Nilotinib Eg tablets should be stored at ambient temperature below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Nilotinib Eg is administered orally as a tablet, usually taken with a low‑fat meal to improve absorption. Patients should follow the specific timing and dietary instructions provided by their prescriber to ensure consistent drug exposure.

The most serious risks include QT interval prolongation, which can lead to potentially fatal arrhythmias, severe hepatic toxicity, and pancreatitis. Regular cardiac monitoring, liver function tests, and assessment for abdominal symptoms are recommended to detect these events early.

Nilotinib Eg should be avoided in patients with a known hypersensitivity to nilotinib or any of its excipients, those with a history of significant QT prolongation, uncontrolled cardiac disease, or severe hepatic impairment. It is also contraindicated in patients taking strong CYP3A4 inhibitors without appropriate dose adjustments.